Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study

(2020) Kristina Boye et al.   DIABETES OBESITY & METABOLISM

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

(2019) Vanita R. Aroda et al.   DIABETES CARE

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

(2019) Richard Pratley et al.   LANCET

Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis

(2019) Solomon Nuhoho et al.   Diabetes Therapy

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes

(2017) Melanie Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE